Juliann Paolicchi, MD
Neurology with Special Qualifications in Child Neurology · Hackensack, NJNPI 1245226059
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $66,104 of the $79,735 with a category attached, or 82.9%. Livanova USA, Inc. accounts for 67.0% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $50,401 and has fallen 99.8% since, to $104 in 2025. Among neurology with special qualifications in child neurology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 161 payments — averaging $495.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$53K
- Greenwich Biosciences, Inc.$12K
- Aquestive Therapeutics, Inc.$7K
- UCB, Inc.$5K
- Aprecia Pharmaceuticals, LLC$1K
- SK Life Science, Inc.$241
- plus $828 from 8 others
Across 5 payments — averaging $20,134 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$101K
What the payments were for
- Consulting fees$2,3303%
- Speaking & faculty fees$66,10483%
- Travel & lodging$7,3439%
- Food & beverage$3,9585%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 65 | $53,416 |
| Greenwich Biosciences, Inc. | 21 | $12,063 |
| Aquestive Therapeutics, Inc. | 37 | $6,618 |
| UCB, Inc. | 12 | $5,348 |
| Aprecia Pharmaceuticals, LLC | 3 | $1,222 |
| SK Life Science, Inc. | 2 | $241 |
| Sunovion Pharmaceuticals Inc. | 7 | $197 |
| Jazz Pharmaceuticals Inc. | 3 | $194 |
| Catalyst Pharmaceuticals, Inc. | 1 | $113 |
| Eisai Inc. | 3 | $91 |
| Neuropace, Inc. | 2 | $85 |
| Neurelis, Inc. | 1 | $82 |
| Mallinckrodt Enterprises LLC | 2 | $35 |
| Novartis | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$50,819
- Epidiolex$11,965
- SYMPAZAN$6,255
- Vimpat$3,500
- VNS - Sentiva$2,250
- Spritam$1,200
- Briviact$750
- APTIOM$125
- Fycompa$113
How this compares
$79,735 in reported general payments places this provider in the 95th percentile of 69 neurology with special qualifications in child neurology providers in New Jersey.
See all neurology with special qualifications in child neurology providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology with special qualifications in child neurology in Hackensack
- Sara RubensteinHackensack$7K
- Michael KatzHackensack$2K
- Rolando SousaHackensack$2K
- Celine LeungHackensack$1K
- Yelena RoshchinaHackensack$313
- Trevor DesouzaMorristown$14K
- Rao PasupuletiHamilton$11K
- Aliza AlterLivingston$9K
- Carlos LastraNew Brunswick$5K
- Jacqueline RomeroMarlboro$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.